The identification of AZA resistance associated with mitochondrial structure and metabolic pathways supports the rationale for combining AZA with BCL-2 inhibition, deepens our understanding of AZA's contribution to the combined therapy, and reveals potential new mitochondrial targets to enhance the therapeutic efficacy of AZA + VEN in AML. This evidence concerns the gene BCL2 and acute myeloid leukemia.